Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Starting statins early after a type 2 diabetes diagnosis could do more than protect your heart — it may also help protect your brain. A large Danish study of over 132,000 people found that initiating statin therapy within one year of a diabetes diagnosis was associated with a 15% lower relative risk of developing dementia over 10 years, compared to no statin use. The earlier the treatment, the greater the benefit.
There's a growing body of evidence that managing cardiovascular risk factors can also protect brain health — and a major new study adds compelling data to that case. Presented at the European Society of Cardiology Congress and published in The Lancet Regional Health – Europe, the research found that statin-naive individuals who started statin therapy within one year of a type 2 diabetes diagnosis had a meaningfully lower risk of developing dementia over the following decade.
The nationwide Danish study tracked 132,585 people diagnosed with type 2 diabetes between 2006 and 2019, sorting them into three groups: no statin use within 5 years, early initiation (within 1 year), and late initiation (1–5 years after diagnosis). Researchers used a rigorous trial-emulation design to minimize observational bias, and followed participants for a median of 7.1 years.
Why it matters: With no cure for dementia on the horizon, prevention is everything. Since statins are already widely prescribed, affordable, and recommended for people with type 2 diabetes to reduce cardiovascular risk, these findings suggest an added — and potentially underappreciated — reason to start them promptly. Clinicians may want to factor dementia risk reduction into conversations about timely statin initiation with newly diagnosed diabetes patients.
